Blog
Articles on running trials, working with CROs and sponsors, and using AI under human control.
When the sponsor owns the platform
Sponsor-owned eClinical platforms shift CRO competition from switching costs to proven performance. Here's why that favours the strongest CROs.
How to win the bid against a global giant
A mid-size CRO can't out-scale a global giant, but it can out-prove one. The agility metrics that belong in your proposal, and the stack that produces them.
Could you prove your data is untouched after a breach?
A leaked token gave attackers two months inside a pharma network. The real question isn't what data was stolen - it's whether the rest can be proven unaltered.
How to adopt AI as a CRO
For CROs, compliant AI isn't a leap of faith - it's an architecture choice. How to adopt AI in clinical trials with the audit trail built in by default.
Becoming a Tech-Enabled CRO
Why CROs that win the next decade need unified infrastructure, not bolted-on tools. How tech-enabled stacks turn vague claims into provable speed and margin.
Bring Your Own CRO
Biotechs don't own the systems running their own trials — their CROs do. Here's why "Bring Your Own CRO" is the new default, and what ownership unlocks.
The First AI Warning Letter: FDA Doubles Down on Mandatory Human Oversight
The FDA issued its first warning letter for AI misuse in drug manufacturing — a firm let AI autonomously create records and determine regulatory requirements without human review. The FDA's position: AI output must be reviewed by qualified humans before finalisation. The article then pitches Carelane's platform as a compliant solution with built-in human-in-the-loop approval workflows.
The Velocity Paradox: Why "Safe" is the New Risky in Clinical Development
The clinical research industry is trapped in a paradox: drug discovery moves fast, but trial operations don't. Discover why speed is no longer a luxury — it's your ultimate risk mitigation strategy, and how Carelane helps sponsors, CROs, and biotechs cut study timelines by 70%.
Carelane sets new standards for clinical research with AI-driven, end-to-end platform
Carelane delivers up to 80% cost and time savings for clinical trials with its AI-powered, end-to-end research platform. Backed by €2.6 million in seed funding, Carelane integrates protocol development, data management, and automation, already supporting 130+ research sites worldwide.
Carelane Raises €800,000 in Pre-Seed Funding to Revolutionize Clinical Trial Software
Carelane has raised €800,000 in pre-seed funding led by HTGF to expand its unified clinical trial platform. By integrating data management, eConsent, sample tracking, and more, Carelane reduces operational burdens and costs by over 80% for researchers and pharma companies.
ECMM has launched the Candida IV study, involving over 100 sites worldwide
Carelane’s innovative platform powered the ECMM's Candida IV study, streamlining site self-registration, real-time monitoring, and collaborative protocol editing to advance multicenter medical mycology research for AROs.
See Carelane in a demo
We'll show you the product on a sample study and answer your questions.
- We walk through study build, data capture and reports on a sample study.
- There is time for your questions, and for your QA or IT colleagues if they join.
- You don't need to prepare or send us anything.
